WO2002009758A3 - Inhibitors of cellular efflux pumps of microbes - Google Patents

Inhibitors of cellular efflux pumps of microbes Download PDF

Info

Publication number
WO2002009758A3
WO2002009758A3 PCT/IN2001/000139 IN0100139W WO0209758A3 WO 2002009758 A3 WO2002009758 A3 WO 2002009758A3 IN 0100139 W IN0100139 W IN 0100139W WO 0209758 A3 WO0209758 A3 WO 0209758A3
Authority
WO
WIPO (PCT)
Prior art keywords
microbes
inhibitors
efflux pumps
compounds
cellular efflux
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2001/000139
Other languages
French (fr)
Other versions
WO2002009758A2 (en
Inventor
Souza Noel J De
Mahesh V Patel
Shrikant V Gupte
Dilip J Upadhyay
Milind C Shukla
Nishith C Chaturvedi
Satish B Bhawsar
Sheela C Nair
Mohammed A Jafri
Habil F Khorakiwala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/640,947 external-priority patent/US6750224B1/en
Priority claimed from US09/850,669 external-priority patent/US6608078B2/en
Priority claimed from PCT/IN2001/000100 external-priority patent/WO2001085728A2/en
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to CA002417799A priority Critical patent/CA2417799A1/en
Priority to AU2001280091A priority patent/AU2001280091A1/en
Priority to EP01958373A priority patent/EP1305048A2/en
Publication of WO2002009758A2 publication Critical patent/WO2002009758A2/en
Publication of WO2002009758A3 publication Critical patent/WO2002009758A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compounds are described which are efflux pump inhibitors of cellular efflux pumps of microbes. Also described are methods of preparing such compounds, methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.
PCT/IN2001/000139 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes Ceased WO2002009758A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002417799A CA2417799A1 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes
AU2001280091A AU2001280091A1 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes
EP01958373A EP1305048A2 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US22220100P 2000-08-01 2000-08-01
US60/222,201 2000-08-01
US09/640,947 2000-08-17
US09/640,947 US6750224B1 (en) 1999-05-07 2000-08-17 Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
IN0000111 2000-11-22
INPCT/IN00/00111 2000-11-22
US28629101P 2001-04-25 2001-04-25
US60/286,291 2001-04-25
US09/850,669 2001-05-07
US09/850,669 US6608078B2 (en) 2000-05-08 2001-05-07 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
INPCT/IN01/00100 2001-05-08
PCT/IN2001/000100 WO2001085728A2 (en) 2000-05-08 2001-05-08 Antibacterial chiral 8-(substituted piperidino)-benzo [i, j] quinolizines, processes, compositions and methods of treatment

Publications (2)

Publication Number Publication Date
WO2002009758A2 WO2002009758A2 (en) 2002-02-07
WO2002009758A3 true WO2002009758A3 (en) 2002-12-27

Family

ID=27517699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2001/000139 Ceased WO2002009758A2 (en) 2000-08-01 2001-07-31 Inhibitors of cellular efflux pumps of microbes

Country Status (4)

Country Link
EP (1) EP1305048A2 (en)
AU (1) AU2001280091A1 (en)
CA (1) CA2417799A1 (en)
WO (1) WO2002009758A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
AU2002361493A1 (en) * 2001-12-13 2003-06-23 Wockhardt Limited New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
EP1918289A3 (en) * 2002-05-28 2009-08-19 Wockhardt Limited Crystalline nadifloxacin arginine salt form
US6664267B1 (en) 2002-05-28 2003-12-16 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
WO2004062674A2 (en) 2003-01-07 2004-07-29 Paratek Pharmaceuticals, Inc. Substituted polyamines as inhibitors of bacterial efflux pumps
GB2403653A (en) * 2003-07-10 2005-01-12 Secr Defence Use of fluoroquinone antibiotics for the treatment of plague
JP5255183B2 (en) * 2003-09-04 2013-08-07 ウォックハート リミテッド Benzoquinolidine-2-carboxylic acid arginine salt tetrahydrate
WO2005026145A2 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
EP1723150A1 (en) 2004-01-13 2006-11-22 Cumbre Pharmaceuticals Inc. Rifamycin imino derivatives effective against drug-resistant microbes
WO2005070940A2 (en) * 2004-01-13 2005-08-04 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
CA2559208A1 (en) 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
DE102004035203A1 (en) 2004-07-21 2006-02-16 Bayer Healthcare Ag Substituted quinolones
DE102005030524A1 (en) 2005-06-30 2007-01-18 Aicuris Gmbh & Co. Kg Substituted quinolones II
DE102006005861A1 (en) 2006-02-09 2007-08-23 Aicuris Gmbh & Co. Kg Substituted quinolones III
US20090264342A1 (en) 2006-02-13 2009-10-22 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
CN101500564B (en) 2006-03-07 2012-07-25 沃克哈特有限公司 Prodrugs of benzoquinolizine-2-carboxylic acid
AU2007225088B2 (en) * 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
US20100234348A1 (en) * 2006-08-04 2010-09-16 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
US7902227B2 (en) 2007-07-27 2011-03-08 Janssen Pharmaceutica Nv. C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents
CA2699151A1 (en) 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
KR101597841B1 (en) 2007-09-12 2016-02-26 교린 세이야꾸 가부시키 가이샤 Spirocyclic aminoquinolones as gsk-3 inhibitors
CA2755120C (en) 2009-03-11 2017-05-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
EP2536408A1 (en) * 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
HRP20180483T1 (en) * 2011-08-31 2018-05-04 Otsuka Pharmaceutical Co., Ltd. Quinolone compound
CN103183684B (en) * 2011-12-29 2015-11-18 杭州师范大学 A kind of quinlone lactone compound and its preparation method and application
CN109486739B (en) * 2018-11-23 2022-02-01 上海海洋大学 Method for inducing vibrio parahaemolyticus to generate levofloxacin drug resistance
KR20240057402A (en) * 2021-07-23 2024-05-02 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 Gram-negative bacterial efflux pump inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300735A1 (en) * 1987-07-20 1989-01-25 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. Antimicrobial pharmaceutical composition
WO1997024128A1 (en) * 1995-12-27 1997-07-10 Bayer Corporation Otic microbial combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300735A1 (en) * 1987-07-20 1989-01-25 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. Antimicrobial pharmaceutical composition
WO1997024128A1 (en) * 1995-12-27 1997-07-10 Bayer Corporation Otic microbial combinations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A.M.DHOPLE, M.A.IBANEZ: "In vivo susceptibility of mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin", ARZNEIMITTEL-FORSCHUNG, vol. 44, no. 4, 1994, pages 563 - 565, XP001108849 *
E.M.MATEU-DE-ANTONIO, M.MARTIN: "In vitro efficacy of several antimicrobial combinations against Brucella canis and Brucella melitensis strains isolated from dogs", VETERINARY MICROBIOLOGY, vol. 45, no. 1, 1995, pages 1 - 10, XP001112917 *
H.C.NEU, N.X.CHIN: "In vitro activity of fleroxacin in combination with other antimicrobial agents", AMERICAN JOURNAL OF MEDICINE, vol. 94, no. 3A, 1993, pages 9S - 16S, XP008008698 *
N.X.CHIN, H.C.NEU: "Combination of ofloxacin and other antimicrobial agents", JOURNAL OF CHEMOTHERAPY (FLORENCE), vol. 2, no. 6, 1990, pages 343 - 347, XP008008692 *
P.VAN DER AUWERA E.A.: "Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, vol. 13, no. 3, 1987, pages 125 - 132, XP008008697 *

Also Published As

Publication number Publication date
WO2002009758A2 (en) 2002-02-07
EP1305048A2 (en) 2003-05-02
CA2417799A1 (en) 2002-02-07
AU2001280091A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
AU2001280091A1 (en) Inhibitors of cellular efflux pumps of microbes
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
UA91002C2 (en) 7-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-polymerase inhibitors
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
WO2005115398A3 (en) Hiv integrase inhibitors
WO2001007030A3 (en) Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs
NO20072058L (en) Inhibitors of the interaction between MDM2 and P53
AU2001264729A1 (en) Thromboxane inhibitors, compositions and methods of use related applications
EP1311269A4 (en) Method of using diketopiperazines and composition containing them
AU2003241464A1 (en) Compositions and methods using proton pump inhibitors
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
NO20024891L (en) Pharmaceutical compositions
WO2004014384A3 (en) Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
TW200510002A (en) Solid pharmaceutical preparation
BRPI0413468A (en) pyrrol-based hmg-coa reductase inhibitors
WO2006023651A3 (en) Extended treatment of multiple sclerosis
UA85394C2 (en) Substituted quinolines as protein tyrosine kinase enzyme inhibitors
WO2006121719A3 (en) Soluble epoxide hydrolase inhibitors and methods of using same
WO2004032908A3 (en) Method of inhibiting angiogenesis
AU2002254212A1 (en) Identification of cellular targets for biologically active molecules
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
WO2004092727A3 (en) Compound libraries and methods for drug discovery
WO2005041904A3 (en) Inhibitors of coronavirus protease and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2417799

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001958373

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001958373

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001958373

Country of ref document: EP